Drug
Aprocitentan clinical trials
Also written ACT-132577.
- studies test it
- 14
- open now
- 1
- in phase 3
- 3
- first study started
- 2015
Keep track of what changes. Save the aprocitentan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
14 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 2 |
| 2020 | 3 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 1
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 0
Idorsia Pharmaceuticals Ltd. (13) · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (1)
Often tested with
Tested in the same studies.
Ethinyl Estradiol (1) · Levonorgestrel (1) · Rosuvastatin (1)
Studies
Open first, then newest update. How each study uses aprocitentan is read from its arms, and is right about nine times in ten.
Testing it · 14
- A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant HypertensionNot yet recruitingPhase 3CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT07635914Written as Aprocitentan tablets(SYH9108)
- A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal ContraceptivesCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT06799884Written as Aprocitentan
- A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its SafetyCompletedPhase 3Idorsia Pharmaceuticals Ltd.NCT03541174Written as Aprocitentan 12.5 mg
- A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-132577 Can Affect Rosuvastatin's Fate in the Body (Amount and Time of Presence in the Blood)CompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT03245229Written as Aprocitentan
- A Study to Evaluate ACT-132577 in Healthy Male SubjectsCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT03100591Written as 14C-radiolabeled ACT-132577
- Clinical Study to Assess Body Fluid Homeostasis After Administration of ACT-132577 in Healthy SubjectsCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT02708004Written as Aprocitentan
- A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male SubjectsCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT02841761Written as Aprocitentan
- Bioequivalence Study of Different Aprocitentan Tablet FormulationsCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT05196399Written as Aprocitentan (Formulation A)
- The Effect of Hepatic Impairment on Aprocitentan PharmacokineticsCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT04252495Written as Aprocitentan
- A Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian SubjectsCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT03586570Written as Aprocitentan 25mg
- To Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and WomenCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT04281342Written as Aprocitentan 25 mg
- Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential HypertensionCompletedPhase 2Idorsia Pharmaceuticals Ltd.NCT02603809Written as Aprocitentan 5 mg
- A Study to Evaluate ACT-132577 in Healthy Subjects and in People With Severe Kidney DiseaseCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT03165071Written as ACT-132577
- A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.WithdrawnPhase 3Idorsia Pharmaceuticals Ltd.NCT04162366Written as Aprocitentan 25 mg
Codes
What other systems call aprocitentan · ClinicalTrials.gg INT006074
- MeSH (NLM) C572762aprocitentanOne source NLM
- UNII (FDA) MZI81HV01PAPROCITENTANConfirmed FDA, NLM, Wikidata
- Wikidata Q27146161aprocitentanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174728AprocitentanOne source FDA
- DrugBank DB15059One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C572762 | aprocitentan | One source NLM |
| UNII (FDA) | MZI81HV01P | APROCITENTAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27146161 | aprocitentan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174728 | Aprocitentan | One source FDA |
| DrugBank | DB15059 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.